Actively Recruiting
Study of Afimkibarts Effects on Medication Processing in Adults With Moderate to Severe Ulcerative Colitis
Led by Hoffmann-La Roche · Updated on 2026-10-16
25
Participants Needed
18
Research Sites
178 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying afimkibart also known as RO7790121 to understand how it may affect the bodys processing of certain medicines that rely on cytochrome P450 enzymes in people with moderately to severely active ulcerative colitis UC. This Phase 1, open-label study focuses on the drug-drug interaction potential by observing changes in the pharmacokinetics of enzyme substrates used in medication metabolism. Participants will receive doses of afimkibart along with a cocktail of cytochrome P450 enzyme substrates, including drugs like midazolam, omeprazole, dextromethorphan, warfarin, and caffeine. The study includes a disease-drug-drug interaction phase followed by an optional long-term extension phase where participants may continue treatment and monitoring. During the study, participants will be monitored through blood tests measuring drug levels and enzyme activity up to approximately 13 weeks. Researchers will evaluate various pharmacokinetic outcomes such as drug concentration over time and metabolite ratios. Safety assessments, including adverse event tracking and serum concentration of afimkibart, will continue for up to 5 years, with the total study participation lasting several years depending on extension enrollment.
CONDITIONS
Brief Title
An Early-Stage Study in Multiple Clinics of How Afimkibart May Affect the Body's Processing of Medicines That Rely on Cytochrome P450 Enzymes in Participants With Ulcerative Colitis
Research Team
R
Reference Study ID Number : GA46438 https://forpatients.roche.com/ No attachments to email below.
F
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here